ClinicalTrials.gg
RecruitingNCT07554222Updated Apr 28, 2026

Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

A Phase 1 interventional study of placebo and Baricitinib tablets in Healthy, Active Non-segmental Vitiligo and Severe Alopecia Areata, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Planned enrollment
12th of 22
160 · median 163
Started
2026
with 4 others
Phase 1
2 of 24
2 open now
Primary completion
2027-12
later than 5 of 12 live
Registered
21st of 24
by date
Lead sponsor
1 of 24
Innovent Biologics (Suzhou) Co. Ltd.

Among the 24 studies in Alopecia Areata with a site in China, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 21st registered.

Alopecia Areata

222 studies on the registry are indexed under Alopecia Areata; 63 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 22 (51%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and severe alopecia areata trial participants. The study is divided into 2 parts, with Part 1 involving healthy trial participants lasting up to 24 weeks, and Part 2 involving active non-segmental vitiligo trial participants and severe alopecia areata trial participants lasting up to 48 weeks.

03

Conditions studied

  • Healthy
  • Active Non-segmental Vitiligo
  • Severe Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Part 1 - Healthy trial participants: Understand and voluntarily sign the form;
  2. Part 1 - Healthy trial participants: Age between 18-45 years (inclusive), male or female;
  3. Part 1 - Healthy trial participants: Weight between 50-120 kg (inclusive), and between 17.0-28.0 kg/m2 (inclusive);
  4. Part 2 - Active non-segmental vitiligo trial participants: 18-65 years old (inclusive), male;
  5. Part 2 - Active non-segmental vitiligo trial participants: Diagnosed with non-segmental vitiligo for ≥3 months and \<2 years;
  6. Part 2 - Active non-segmental vitiligo trial participants: Total affected BSA 3-50%, and facial affected BSA ≥ 0.5%; T-VASI 3-50 (inclusive), and F-VASI ≥0.5; ≥1 active lesion;
  7. Part 2 - : Male participants of agree to use highly effective and avoid sperm donation for 6 months after the last dose.
  8. Part 2 - Severe alopecia areata trial participants: 18-60 years old (inclusive), male;
  9. Part 2 - Severe alopecia areata trial participants: Meet the following severe alopecia areata criteria: a) SALT ≥50% (i.e., AA-IGA 3-4 grade) b) No spontaneous remission in the past 6 months (spontaneous remission defined as SALT reduction by ?10 points) c) Current duration of severe alopecia areata ≥6 months and \<4 years;
  10. All participants: Participants of reproductive potential agree to use highly effective contraception and avoid sperm or egg donation for 6 months after the last dose.

Exclusion criteria

Exclusion criteria

  1. All participants: Those who are allergic to any component of IBI3013;
  2. All participants: Those who cannot tolerate subcutaneous injection;
  3. All participants: History of live or attenuated within 30 days prior to randomization, or expected to receive such vaccines during the study period until 3 months after the last dose of the drug;
  4. All participants: Donated blood or lost ≥400 mL of blood within 3 months before screening;
  5. All participants: History of herpes zoster or disseminated herpes simplex (single episode), or recurrent (more than one episode) localized herpes zoster;
  6. All participants: Known history of active tuberculosis or clinical manifestations suggestive of tuberculosis, or positive interferon-gamma release assay unsuitable for participation;
  7. All participants: Abnormal vital signs, serum virology tests, laboratory tests, , or other examinations with clinical significance, and deemed unsuitable for the study by the investigator;
  8. All participants: Received specific treatment within the time frame specified in the protocol, or participated in other investigational drug studies within the specified time;
  9. All participants: History of drug abuse, drug dependence, or positive drug screening results during the screening period within 12 months;
  10. All participants: Pregnant or lactating women;
  11. All participants: Coexisting diseases at screening or previously, deemed unsuitable for clinical trials;
  12. Active non-segmental vitiligo/Severe alopecia areata trial participants: Previous or coexisting diseases, which may affect the efficacy or safety evaluation of the study as assessed by the investigator;
  13. Active non-segmental vitiligo trial participants: Coexisting segmental, undetermined type, or mixed-type vitiligo, or other skin pigmentation disorders, or other skin-related abnormalities that may affect the assessment of the study;
  14. Severe alopecia areata trial participants: Currently diagnosed with primary diffuse AA or ophiasis AA; or other types of hair loss that may interfere with AA evaluation;
  15. Severe alopecia areata trial participants: Previously received oral JAK inhibitors with poor response; 16. Severe alopecia areata trial participants: Acute myocardial infarction, unstable ischemic heart disease, stroke, chronic heart failure ( class III/IV) within 12 weeks prior to screening; or previous history of deep vein thrombosis, or high risk of deep vein thrombosis as assessed by the investigator; or severe neuropsychiatric disorder, deemed unsuitable for the study by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Baricitinib tablets

    oral, 2mg, once daily

    Drug: Baricitinib tablets

  • Placebo comparator
    placebo

    subcutaneous injection/intravenous infusion,single or multiple dosing

    Drug: placebo

  • Experimental
    IBI3013

    subcutaneous injection/intravenous infusion,single or multiple dosing

    Drug: IBI3013

Interventions

  • Drugplacebo

    placebo

  • DrugBaricitinibStudies of BaricitinibBaricitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Baricitinib tablets

  • DrugIBI3013

    Recombinant anti-Interleukin-15 (IL-15) monoclonal antibody injection

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with at least one treatment-emergent adverse event

    Time frame: up to 24 weeks

  2. Part 1: Number of participants with at least one Serious treatment-emergent adverse event

    Time frame: up to 24 weeks

  3. Part 2: Number of participants with at least one treatment-emergent adverse event

    Time frame: up to 48 weeks

  4. Part 2: Number of participants with at least one Serious treatment-emergent adverse event

    Time frame: up to 48 weeks

Secondary outcomes

  1. Part 1: Cmax following a single dose of IBI3013.

    Time frame: up to 24 weeks

  2. Part 1: Tmax following a single dose of IBI3013.

    Time frame: up to 24 weeks

  3. Part 1: AUC following a single dose of IBI3013.

    Time frame: up to 24 weeks

  4. Part 1: Cmin following a single dose of IBI3013.

    Time frame: up to 24 weeks

  5. Part 1: CL/F or CL following a single dose of IBI3013.

    Time frame: up to 24 weeks

  6. Part 1: Vd/F or Vd following a single dose of IBI3013.

    Time frame: up to 24 weeks

  7. Part 1: T1/2 following a single dose of IBI3013.

    Time frame: up to 24 weeks

  8. Part 1: Positive rate of anti-drug antibody following a single dose of IBI3013.

    Time frame: up to Day85

  9. Part 2: Cmax following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  10. Part 2: Tmax following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  11. Part 2: AUC following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  12. Part 2: Cmin following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  13. Part 2: CL/F following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  14. Part 2: Vd/F following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  15. Part 2: T1/2 following multiple doses of IBI3013.

    Time frame: up to 48 weeks

  16. Part 2: Positive rate of anti-drug antibody following multiple doses of IBI3013.

    Time frame: up to 28 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 28, 2026
StartActual
Apr 18, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07554222
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Apr 18, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 28, 2026

Study contacts

juan chen
Contact
juan.chen01@innoventbio.com
021 3183 7200

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion